dm+d

Unassigned

New Medicines

Type 1 complex regional pain syndrome (also known as reflex sympathetic dystrophy)

Information

New molecular entity
Abiogen Pharma
Gruenenthal

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Potent osteoclast inhibitor - reduces osteoclast activity by inhibiting the farnesyl pyrophosphate synthase (FPPS) enzyme
Incidence rates of Complex Regional Pain Syndrome (CRPS) are around 26 per 100,000 patient years in Europe. CRPS has a mean age of onset of 46 years. It may occur in up to 5% of all injuries, up to 15% of peripheral nerve injuries and following 10-30% of fractures [2].
Type 1 complex regional pain syndrome (also known as reflex sympathetic dystrophy)
Intravenous infusion

Evidence based evaluations